Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... New York (PRWEB) October 02, 2014 ... to announce funding received to investigate therapeutics directed ... disease. A grant award from the Small Business ... (NIA), National Institutes of Health (NIH) is entitled ... Therapeutics." The company also received a SBIR Matching ...
(Date:10/2/2014)... MO (PRWEB) October 02, 2014 Permian ... business in the St. Louis, Missouri, area on October ... has become a leading plastic injection molder in the ... machines and is a supplier to many Fortune 500 ... customer support every step of the way, from concept ...
(Date:10/2/2014)... 02, 2014 At a time when many ... has introduced a new kind of squeeze aimed at ... the Scienceware® Squeeze Rite™ Wash Bottle , catalog no. ... within the bottle reduces the waste of reagents, solutions and ... liquids. , “Easier to squeeze when compared to standard 500ml ...
(Date:10/2/2014)...  NKT Therapeutics today announced that the U.S. ... designation to NKTT120, the company,s lead therapeutic being ... NKTT120 is a humanized monoclonal antibody that specifically ... has been demonstrated to be a key mediator ... cell disease.  Fast Track designation is intended to ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2
... article profiling the significant rise in valuation of ... is true product innovation through focused R&D efforts that's currently ... valuation. , ,While Genentech had revenues of $4.6 billion in ... ,This surpasses Amgen's top position of $72.2 billion, is pretty ...
... and the Endpoint Exchange Network said on Tuesday ... be able to exchange check data and images, starting with ... an IT service provider claiming 4,000 financial clients. Endpoint Exchange ... Metavante , the technology arm of Marshall & Ilsley ...
... Corp. said on Wednesday it has agreed to buy ... spinoff, for $600 million in cash. , ,Bone Care and ... $2 billion and almost 7,000 employees worldwide, plan to complete ... reported healthy quarterly profits and revenues. Bone Care tallied its ...
Cached Biology Technology:Drug innovation beats marketing, patents and mergers 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3
(Date:9/30/2014)... Pollution in urban and farm runoff in Hawaii is ... finds. , The study, published Tuesday in the ... in the runoff ends up in algae that the ... animals, eyes, flippers and internal organs. , Scientists at ... Oceanic and Atmospheric Administration (NOAA) conducted the study to ...
(Date:9/30/2014)... . , Animals ... such as exposure to predators. Researchers from the Max ... study on different populations of great tits that risk-taking ... High metabolic rates and low temperatures were associated with ... more likely to approach potential predators. , The readiness ...
(Date:9/29/2014)... of gut bacteria called Clostridium ramosum , coupled with ... work is published this week in mBio , the ... , A research team from the German Institute of Human ... bacteria including C. ramosum gained weight when fed ... ramosum were less obese even when consuming a high-fat ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2Gut bacteria promote obesity in mice 2
... NIH-supported scientists will be presenting their latest research findings ... Research in Otolaryngology (ARO). When: February 19-23, 2011 ... Additional Information: Research topics to be presented by scientists ... Communication Disorders (NIDCD) will include: Deafness ...
... will disappear by 2200 as a result of warming ... says a new study by the University of Colorado ... The carbon resides in permanently frozen ground ... warming temperatures, which will impact not only the climate ...
... Scientists are reporting for the first time that ... potential to act as endocrine disruptors, which can interfere ... is not caused by microcystin toxins, long recognized as ... yet unidentified substances. As a result, the scientists are ...
Cached Biology News:NIDCD research at ARO Midwinter Meeting 2NIDCD research at ARO Midwinter Meeting 3NIDCD research at ARO Midwinter Meeting 4NIDCD research at ARO Midwinter Meeting 5NIDCD research at ARO Midwinter Meeting 6NIDCD research at ARO Midwinter Meeting 7Thawing permafrost likely will accelerate global warming 2Thawing permafrost likely will accelerate global warming 3
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
Biology Products: